+ Follow EUROPEAN LEAGUE AGAINST RHEUMATISM Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1499192
[Title] => Consider Chikungunya in new onset polyarthritis
[Summary] => Physicians should consider the possibility of Chikungunya virus in patients who present with new symmetric polyarthritis, especially if they have just returned from an endemic region such as the Caribbean, according to researchers.
[DatePublished] => 2015-09-12 10:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 691717
[Title] => Roche announces new study data on rheumatoid arthritis treatment
[Summary] => Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 619244
[Title] => Low-dose colchicine effective for acute gout
[Summary] => Low-dose colchicine appeared to be as effective as a more conventional dose in treating acute gout flares, but produced far fewer side effects in randomized, double blind, placebo-controlled trial in 185 patients.
[DatePublished] => 2010-10-10 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 590859
[Title] => New hope for children with systemic juvenile idiopathic arthritis
[Summary] => Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
[DatePublished] => 2010-07-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 533908
[Title] => Two predictors of early arthritis identified
[Summary] => An observational study of 395 patients with suspected early arthritis identified two factors that predicted a diagnosis of rheumatoid arthritis within a year’s time.
[DatePublished] => 2009-12-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[5] => Array
(
[ArticleID] => 127573
[Title] => Meloxicam is safe, says study
[Summary] => PRAGUE — New data presented recently at the 16th European League Against Rheumatism (EULAR) Congress showed that the risk of heart attacks, other cardiac events and renal toxicity in patients taking the nonsteroid anti-inflammatory (NSAID) meloxicam (Mobic) is low.
The result was similar for patients taking meloxicam and two other commonly prescribed NSAIDs. Moreover, no effects on bleeding time were observed in healthy volunteers with meloxicam at higher than recommended doses.
[DatePublished] => 2001-07-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
EUROPEAN LEAGUE AGAINST RHEUMATISM
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1499192
[Title] => Consider Chikungunya in new onset polyarthritis
[Summary] => Physicians should consider the possibility of Chikungunya virus in patients who present with new symmetric polyarthritis, especially if they have just returned from an endemic region such as the Caribbean, according to researchers.
[DatePublished] => 2015-09-12 10:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 691717
[Title] => Roche announces new study data on rheumatoid arthritis treatment
[Summary] => Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 619244
[Title] => Low-dose colchicine effective for acute gout
[Summary] => Low-dose colchicine appeared to be as effective as a more conventional dose in treating acute gout flares, but produced far fewer side effects in randomized, double blind, placebo-controlled trial in 185 patients.
[DatePublished] => 2010-10-10 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 590859
[Title] => New hope for children with systemic juvenile idiopathic arthritis
[Summary] => Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
[DatePublished] => 2010-07-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 533908
[Title] => Two predictors of early arthritis identified
[Summary] => An observational study of 395 patients with suspected early arthritis identified two factors that predicted a diagnosis of rheumatoid arthritis within a year’s time.
[DatePublished] => 2009-12-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[5] => Array
(
[ArticleID] => 127573
[Title] => Meloxicam is safe, says study
[Summary] => PRAGUE — New data presented recently at the 16th European League Against Rheumatism (EULAR) Congress showed that the risk of heart attacks, other cardiac events and renal toxicity in patients taking the nonsteroid anti-inflammatory (NSAID) meloxicam (Mobic) is low.
The result was similar for patients taking meloxicam and two other commonly prescribed NSAIDs. Moreover, no effects on bleeding time were observed in healthy volunteers with meloxicam at higher than recommended doses.
[DatePublished] => 2001-07-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
